Estrella Immunopharma (NASDAQ:ESLA) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.18) by 72.22 percent. This is a 44.44 percent increase over losses of $(0.09) per share from the same period last year.